Among planned EU drug marketing authorization applications (MAAs) that the European Medicine Agency most recently considered for fast-track review is one from Biogen and Eisai for lecanemab, the Alzheimer’s disease treatment that could potentially be approved in the US on 6 January.
Lecanemab is one of three investigational products that were listed as being up for consideration for an accelerated assessment on the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?